{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T13:25:11Z","timestamp":1696166711942},"reference-count":18,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,9,6]],"date-time":"2015-09-06T00:00:00Z","timestamp":1441497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT01704755"],"award-info":[{"award-number":["NCT01704755"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background &amp; Aims<\/jats:title><jats:p>Thrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic synthetic dysfunction respectively. Patients infected with hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) with these surrogates have reduced likelihood of sustained virologic response and increased risk for hepatic decompensation or death when treated with peginterferon\/ribavirin plus either telaprevir or boceprevir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a post\u2010hoc analysis of the <jats:styled-content style=\"fixed-case\">TURQUOISE<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> clinical trial in patients with cirrhosis to examine the impact of these surrogates on efficacy and safety of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 380 genotype 1\u2010infected patients in <jats:styled-content style=\"fixed-case\">TURQUOISE<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>, 104 had either a platelet count &lt;100\u00a0\u00d7\u00a010<jats:sup>9<\/jats:sup>\/L or albumin &lt;3.5\u00a0g\/dl. Sustained virologic response rates were 89 and 97% in patients with thrombocytopaenia, and 84 and 89% in patients with hypoalbuminaemia after 12 and 24\u00a0weeks of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin respectively. These rates were similar to those observed in the overall study population (92 and 97% for 12 and 24\u00a0weeks). <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotype 1a\u2010infected patients with thrombocytopaenia or hypoalbuminaemia had higher response rates when treated for 24\u00a0weeks, whereas only 1 of 35 genotype 1b patients did not achieve a sustained virologic response. Adverse event rates and discontinuations because of adverse events were low.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The findings of these analyses support the use of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with ribavirin in these subpopulations with cirrhosis. Genotype 1a\u2010infected patients with indicators of portal hypertension may benefit from a 24\u2010week treatment duration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.12931","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T06:40:51Z","timestamp":1438929651000},"page":"2358-2362","source":"Crossref","is-referenced-by-count":12,"title":["Ombitasvir\/paritaprevir\/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia"],"prefix":"10.1111","volume":"35","author":[{"given":"Xavier","family":"Forns","sequence":"first","affiliation":[{"name":"Liver Unit Hospital Clinic CIBERehd IDIBAPS Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[{"name":"The Texas Liver Institute\/University of Texas Health Science Center San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Pedrosa","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[{"name":"La Fe University Hospital and CIBERehd Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Hannover Medical School Hannover Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[{"name":"Medical University of Vienna Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[{"name":"Liver Institute of Virginia Bon Secours Health System Newport News VA USA"},{"name":"Liver Institute of Virginia Bon Secours Health System Richmond VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Fried","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill UNC Liver Center Chapel Hill NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lovell","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Trinh","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Lopez\u2010Talavera","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Everson","sequence":"additional","affiliation":[{"name":"University of Colorado Denver School of Medicine Aurora CO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.002"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305667"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.035"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.051"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70050-2"},{"key":"e_1_2_8_16_1","unstructured":"FlammSL EversonGT CharltonMR et\u00a0al.Ledispasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective multicenter study. Presented at American Association for the Study of Liver Disease Boston MA November 11 2014."},{"key":"e_1_2_8_17_1","unstructured":"ReddyKR EversonGT FlammSL et\u00a0al.Ledipasvir\/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective multicenter study. Presented at American Association for the Study of Liver Diseases Boston MA November 9 2014."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.12931","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.12931","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.12931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T14:51:24Z","timestamp":1695567084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.12931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,6]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/liv.12931"],"URL":"https:\/\/doi.org\/10.1111\/liv.12931","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,6]]}}}